Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2014
Price : $35 *
At a glance
- Drugs Zuretinol acetate (Primary)
- Indications Age-related macular degeneration; Eye disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors QLT
- 05 Dec 2014 Primary endpoint has not been met (low luminance low contrast best-corrected visual acuity [LLLC BCVA] measured at multiple time points), according to a QLT media release.
- 05 Dec 2014 Results published in a QLT media release.
- 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History